In a research note published by Peter Welford,
Jefferies advises its customers to buy the stock. The target price has
been revised downwards and is now set at CHF 360 as compared to CHF 370
previously..
https://www.marketscreener.com/ROCHE-HOLDING-AG-9364975/news/ROCHE-HOLDINGS-AG-Receives-a-Buy-rating-from-Jefferies-30413569/
Wednesday, April 15, 2020
NOVO NORDISK Receives a Buy rating from UBS
Already positive, the research from UBS and
its analyst Michael Leuchten still consider the stock as a Buy
opportunity.. The target price remains unchanged at DKK 425.
https://www.marketscreener.com/NOVO-NORDISK-A-S-1412980/news/NOVO-NORDISK-Receives-a-Buy-rating-from-UBS-30413957/
https://www.marketscreener.com/NOVO-NORDISK-A-S-1412980/news/NOVO-NORDISK-Receives-a-Buy-rating-from-UBS-30413957/
Proxy advisers split over endorsing Bayer management at AGM
Shareholder advisory groups are divided over whether to endorse the management and directors at German drugs and pesticides company Bayer, according to recommendations submitted by proxy voting firms.
Bayer is due to host its annual general meeting on April 28 but the
company still faces potentially huge litigation risks stemming from its
$63 billion purchase of Monsanto in 2018.
One leading shareholder advisory firm, ISS, on Tuesday backed a motion to support the actions of the management and supervisory board.
“Qualified support for both discharge proposals is warranted as there does not appear to be any evidence that the boards have not fulfilled their fiduciary duties for the 2019 fiscal year,” it said.
However another large advisory group, Glass Lewis, said on April 6 that investors should abstain because of ongoing proceedings regarding pesticide Roundup, acquired via the takeover of Monsanto.
Shares in Bayer have shed more than a quarter of their value since mid-2018 when the company lost a U.S. lawsuit claiming that glyphosate-based Roundup causes cancer.
Bayer denies that glyphosate or Roundup cause cancer and is appealing. The company has received tentative backing from some legal and regulatory experts.
The U.S. Environmental Protection Agency (EPA) also reaffirmed this year that glyphosate was safe.
In December, the U.S. Justice Department said in a so-called amicus brief that a federal appeals court should reverse the lower court verdict finding Bayer liable in a Californian Roundup case.
Major regulators, including those overseeing European and U.S pesticide markets, have deemed it safe but the World Health Organization’s International Agency for Research on Cancer (IARC) concluded in 2015 that glyphosate probably causes cancer.
Glass Lewis said the ongoing proceedings could have a bearing on how the boards’ performance is viewed, so recommended that shareholders abstain from voting on a ratification proposal.
“We continue to believe that shareholders are not currently in a position to meaningfully assess whether the ratification of the acts of management board members for the past fiscal year is currently in their best interests,” it said.
One leading shareholder advisory firm, ISS, on Tuesday backed a motion to support the actions of the management and supervisory board.
“Qualified support for both discharge proposals is warranted as there does not appear to be any evidence that the boards have not fulfilled their fiduciary duties for the 2019 fiscal year,” it said.
However another large advisory group, Glass Lewis, said on April 6 that investors should abstain because of ongoing proceedings regarding pesticide Roundup, acquired via the takeover of Monsanto.
Shares in Bayer have shed more than a quarter of their value since mid-2018 when the company lost a U.S. lawsuit claiming that glyphosate-based Roundup causes cancer.
Bayer denies that glyphosate or Roundup cause cancer and is appealing. The company has received tentative backing from some legal and regulatory experts.
The U.S. Environmental Protection Agency (EPA) also reaffirmed this year that glyphosate was safe.
In December, the U.S. Justice Department said in a so-called amicus brief that a federal appeals court should reverse the lower court verdict finding Bayer liable in a Californian Roundup case.
Major regulators, including those overseeing European and U.S pesticide markets, have deemed it safe but the World Health Organization’s International Agency for Research on Cancer (IARC) concluded in 2015 that glyphosate probably causes cancer.
Glass Lewis said the ongoing proceedings could have a bearing on how the boards’ performance is viewed, so recommended that shareholders abstain from voting on a ratification proposal.
“We continue to believe that shareholders are not currently in a position to meaningfully assess whether the ratification of the acts of management board members for the past fiscal year is currently in their best interests,” it said.
https://www.marketscreener.com/BAYER-AG-436063/news/Bayer-Proxy-advisers-split-over-endorsing-Bayer-management-at-AGM-30413000/
SANOFI: Bernstein remains with its Buy rating
In a research note published by Wimal Kapadia, Bernstein advises its
customers to buy the stock. The target price is decreased from EUR 108
to EUR 105.
https://www.marketscreener.com/SANOFI-4698/news/SANOFI-Bernstein-remains-its-Buy-rating-30413522/
https://www.marketscreener.com/SANOFI-4698/news/SANOFI-Bernstein-remains-its-Buy-rating-30413522/
FDA OKs emergency use of Chembio rapid blood test for COVID-19
The FDA has authorized the emergency use of Chembio Diagnostics’ (CEMI +3.2%) point-of-care DPP COVID-19 System for the rapid detection of IgM and IgG antibodies to SARS-CoV-2 from a fingerstick sample.
The company launched the product earlier this month which the FDA is allowing during the pandemic for properly validated tests.
https://seekingalpha.com/news/3560877-fda-oks-emergency-use-of-chembio-rapid-blood-test-for-covidminus-19Moderna teams up with Ginkgo Bioworks to improve manufacturing
Privately held Ginkgo Bioworks announces a project with mRNA vaccine developer Moderna (MRNA -2.2%) aimed at optimizing the latter’s processes for making key raw materials for its vaccines, including its COVID-19 candidate.
Ginkgo is contributing its platform infrastructure
and know-how to help Moderna to more quickly improve the efficiency of
its processes, adding that it has committed to providing $25M in free
work to support the effort.
https://seekingalpha.com/news/3560881-moderna-teams-up-ginkgo-bioworks-to-improve-manufacturing-processesAdial Pharma nabs new patent in U.S.
The USPTO has issued new patent to Adial Pharmaceuticals (ADIL +22.3%), titled “Serotonin Transporter Gene and Treatment of Opioid-Related Disorders”.
This patent covers the treatment of Opioid Use
Disorder by administering AD04, an antagonist of the serotonin-3
receptor (5-HT3), to patients with the LL and TT genotypes, which may be
identified by genetic test.
The issued patent discloses the differences in
treatment and diagnosis based on the LL or SS genotypes as well as on a
single nucleotide polymorphism of the SERT gene, the TT genotype of the
3′ UTR SNP rs1042173.
The company expects market exclusivity for AD04 through 2032, plus potential Hatch-Waxman extensions through 2037.
https://seekingalpha.com/news/3560887-adial-pharma-nabs-new-patent-in-u-s
Subscribe to:
Comments (Atom)